Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEQTOR sequence study of everolimus versus STZ-5FU in advanced pancreatic neuroendocrine tumors
NL-OMON55657Phase 3Active, not recruiting
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, streptozocin and fluorouracil in islet cell tumor and islet cell carcinoma (ICC) (2 arms), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoints: 12-month first-course progression-free survival rate and Safety and treatment exposure. Started Mar 2016; status: active, not recruiting.
02
Drugs
everolimusstreptozocinfluorouracil
03
Conditions
islet cell tumorislet cell carcinoma (ICC)
Beyond the preview
Go deeper on NL-OMON55657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55657.